

ASX Announcement

Positive new HER-Vaxx HERIZON data presented at ESMO Asia Congress 2022

Sydney, Australia, 5 December 2022: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased to announce positive new data regarding overall survival results in its HER-Vaxx HERIZON study as provided in an oral presentation at the ESMO Asia Congress 2022 held in Singapore.

Speaking to the Congress on Sunday 4 December 2022, principal investigator Marina Maglakelidze outlined the study design, information regarding demographics and characteristics of the 36 patients in the trial, and data covering safety and adverse events.

Key conclusions of the overall survival benefit of HER-Vaxx included:

- HER-Vaxx + chemotherapy showed a statistically significant 42% overall survival benefit compared to chemotherapy alone (13.9 vs 8.3 months)
- Duration of response is longer in the HER-Vaxx + chemotherapy arm over chemotherapy alone (30 vs 19 weeks)
- Vaccination with HER-Vaxx induced persistent HER-2 specific antibodies which correlated with clinical response as proof of concept for a first-in-class B-cell immunotherapy based on HER-2 peptides
- No significant additive toxicity was seen when HER-Vaxx was administered in combination with chemotherapy

The full presentation provided at ESMO can be viewed at: <https://www.imugene.com/conference-presentations>.

The oral presentation and abstract, number 74MO, was titled 'HERIZON Overall Survival Results: A study of IMU-131, a HER2 Targeting Peptide Vaccine, Plus Standard of Care Chemotherapy in Patients with HER2 Overexpressing Metastatic or Advanced Gastric/GEJ Cancer'.

The HERIZON study was a Phase 2 clinical trial of Imugene's HER-Vaxx technology in Her-2/Neu overexpressing advanced/metastatic gastric/GEJ cancer. HER-Vaxx is a B-cell activating cancer immunotherapy designed to treat tumours that overexpress the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. The immunotherapy is constructed from several B cell epitopes derived from the extracellular domain of HER2/neu.



For more information please contact:

Leslie Chong

Managing Director and Chief Executive Officer

info@imugene.com

Investor Enquiries

investor@imugene.com

Media Enquiries

Matt Wright

matt@nwrcommunications.com.au

Follow us on Twitter @TeamImugene

Like us on Facebook @Imugene

Connect with us on LinkedIn @Imugene Limited

Watch us on YouTube @ImugeneLimited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer

Imugene Limited, Level 3, 62 Lygon Street, Carlton, VIC, 3053, Australia